Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663065 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety of PAZ-417 in Healthy Elderly Adults
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00663065 is a Phase 1 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 40 participants.
The verdict
NCT00663065, a Phase 1 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is study to determine the safety of PAZ-417 in healthy adults over 65.
Interventions
- DRUG PAZ-417
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00663065
The ClinicalTrials.gov registry entry for NCT00663065 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PAZ-417 is the first listed.
NCT00663065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00663065 about?
NCT00663065 is a clinical study titled "A Study of the Safety of PAZ-417 in Healthy Elderly Adults". This is study to determine the safety of PAZ-417 in healthy adults over 65.
What is the current status of trial NCT00663065?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00663065?
The interventions under investigation include: PAZ-417 (DRUG).
Who is sponsoring clinical trial NCT00663065?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.